Dentsply celebrates the relaunch of popular anaesthetic Citanest®

On October 22nd 2010, DENTSPLY Marketing Director Gary Marvin sat down to chair a press conference on the re-release of Citanest – the local dental anaesthetic that had proved one of the company’s biggest success stories. The release had caused quite a stir, as the product had proved a favourite amongst dental practitioners for over a decade. The point of this press conference, said Gary, was to reassure the dental industry that Citanest was back for good.

The Citanest story began in 2000 when DENTSPLY acquired the licence to produce it from the pharmaceutical company AstraZeneca. DENTSPLY quickly established the product as a market leader but when manufacture was moved to a new site, supply was rapidly outpaced by demand. This served to reiterate the popularity of the anaesthetic, as the Citanest-shaped gap in the market proved hard to fill. Containing felypressin instead of adrenaline, Citanest is unique in the world of dental anaesthetics as it can be safely administered to all patients without the risk of cardiac problems and, as it does not contain latex, is also the ideal choice to eliminate the risk of allergic reaction. Just as effective as lidocaine-based anaesthetics but 40 per cent less toxic and with excellent tolerance levels, Citanest, with its patented active ingredient octapressin, is a safe and reliable choice for any dentist.

Forced to switch back to lidocaine based products or plain solutions containing no vasoconstrictors, many dentists were initially chagrined at the loss of Citanest, with its patented properties of Citanest, provides one of the best anaesthetics available, with excellent tolerance rates and, as it does not contain adrenaline, Citanest is a safe and reliable choice for any dentist.

The key to the administration of local anaesthetic is the avoidance of blood vessels during the injection. The excitement running through the industry surrounding the re-release of Citanest is tangible and people from all over the dental community have expressed their gratitude at the news that this unique and outstanding product is now available in plentiful supply. Gary Marvin, in the wake of his press conference, summed it up succinctly: “I hope that dentists can now breathe a sigh of relief”.

The key to the administration of local anaesthetic is the avoidance of blood vessels during the injection. This has proved problematic for many years as, in testing to make sure no blood vessels have been hit by aspirating (withdrawing the bun a little and reinserting it), the dentist can, with a slight shake of the hand, accidentally re-enter in the wrong place, with potentially serious effects. With the self-aspirating syringe however, aspiration requires little movement from the practitioner. This product has had excellent feedback from practitioners and, combined with the unique properties of Citanest, provides one of the safest available methods of anaesthetising dental patients. DENTSPLY are also reintroducing Xylocaine, which is an effective, highly local, traditional anaesthetic with a better tolerance rate than many other brands. Xylocaine will be available alongside Citanest at competitive prices to celebrate the re-launch.

Dentists give three cheers for the return of Citanest®

For more information, or to book an appointment with your local DENTSPLY Product Specialist, call: 0800 072 5315 or visit www.DENTSPLY.co.uk